NIKI (Niki BioSolutions) EBIT: $-1.42 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKI Niki BioSolutions Inc NIKI
56 GF Score
Price $9.54
GF Value $11.69
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Niki BioSolutions EBIT?

Niki BioSolutions NIKI +11.06% 56 EBIT is $-1.42 Mil as of Dec. 2025. GuruFocus rates NIKI with a GF Score™ of 56/100 and a GF Value™ of $11.69 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Niki BioSolutions's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-0.83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Niki BioSolutions's annualized ROC % for the quarter that ended in Dec. 2025 was -17.81%. Niki BioSolutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Niki BioSolutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 87.78%.

Niki BioSolutions  (NAS:NIKI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Niki BioSolutions's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-3.3 * ( 1 - 0% )/( (18.524 + 18.541)/ 2 )
=-3.3/18.5325
=-17.81 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17.579 - 0.991 - ( 2.273 - max(0, 4.416 - 2.48+2.273))
=18.524

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18.691 - 1.151 - ( 3.453 - max(0, 4.594 - 3.593+3.453))
=18.541

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Niki BioSolutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.3/( ( (0 + max(-0.793, 0)) + (0 + max(-1.011, 0)) )/ 2 )
=-3.3/( ( 0 + 0 )/ 2 )
=-3.3/0
= %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.198) - (0.991 + 0 + 8.8817841970013E-16)
=-0.793

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.14) - (1.151 + 0 + 0)
=-1.011

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Niki BioSolutions's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-1.415/-1.612
=87.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niki BioSolutions EBIT Related Terms

Niki BioSolutions EBIT Historical Data

* Premium members only.

The historical data trend for Niki BioSolutions's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niki BioSolutions EBIT Chart

Niki BioSolutions Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only -19.21 -17.17 -10.60 -3.00 -1.82

Niki BioSolutions Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 0.28 0.00 -0.59 -0.83

NIKI vs LABT, NCNA, SNGX: EBIT Comparison

For the Biotechnology subindustry, Niki BioSolutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Niki BioSolutions EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Niki BioSolutions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Niki BioSolutions's EV-to-EBIT falls into.


NIKI
56GF Score
Niki BioSolutions Inc NIKI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niki BioSolutions EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-1.42 Mil mean?
Niki BioSolutions (NIKI) has a EBIT of $-1.42 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Niki BioSolutions.
Is Niki BioSolutions' EBIT too high?
Niki BioSolutions' current EBIT is $-1.42 Mil. Overall, Niki BioSolutions has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' EBIT compare to LABT and NCNA?
Niki BioSolutions' EBIT of $-1.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Niki BioSolutions. Niki BioSolutions's current EBIT is $-1.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Niki BioSolutions (NIKI) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.69, compared to a current price of $9.54 — trading 18.4% below its estimated fair value. The current EBIT is $-1.42 Mil. Niki BioSolutions' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current EBIT is $-1.42 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niki BioSolutions (NIKI) Overvalued in 2026?

Based on GuruFocus' analysis, Niki BioSolutions stock appears to be undervalued. The current stock price of $9.54 is trading 18.4% below its estimated GF Value™ of $11.69. GuruFocus considers Niki BioSolutions to be Modestly Undervalued.

Key valuation signals for NIKI:

  • EBIT: $-1.42 Mil
  • GF Value™: $11.69 vs. price of $9.54 (18.4% below fair value)
  • GF Score™: 56/100 with 1 warning sign

No single metric tells the full story. See the NIKI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Niki BioSolutions Business Description

Address 17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
56GF Score

Get the complete analysis for NIKI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.54
Price
$11.69
GF Value